Drug intelligence / Profile preview

carboplatin + everolimus + paclitaxel

Development stage: Unknown
Lead developer: Johnson Matthey
Modality: Small Molecules
Administration: Intravenous, Oral

Overview

A combination therapy consisting of carboplatin (a platinum-based alkylating agent), everolimus (an mTOR inhibitor), and paclitaxel (a taxane chemotherapy drug). This regimen targets cancer cells through multiple mechanisms: carboplatin forms DNA crosslinks preventing replication, everolimus inhibits the mTOR pathway (specifically mTORC1), and paclitaxel stabilizes microtubules disrupting cell division. The combination has been studied in clinical trials for various cancer types including melanoma, large-cell neuroendocrine carcinoma (LCNEC), and metastatic breast cancer.

Brand names: AfinitorTaxolParaplatin
Other names: everolimus + carboplatin + paclitaxel

Targets

Mechanistic target of rapamycin complex 1DNA

Beyond the preview

Go deeper on carboplatin + everolimus + paclitaxel.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on carboplatin + everolimus + paclitaxel.

Explore the full profile